Psychedelic Spotlight News

Texas Further Embraces Psychedelics with Launch of Center for Psychedelic Research and Therapy

December 29, 2021June 2, 2024 Learn, Research

Research will focus on how various psychedelics can be used under proper supervision and guidance to treat severe depression, anxiety and PTSD.

Interview with Matt Stang, CEO of Delic Corp

December 29, 2021June 2, 2024 Interviews, Listen, Podcasts

Co-Founder and CEO, Matt Stang, gives us an overview of the company’s clinics, Delic Labs and more.

Ketamine Rapidly Reduces Depression, According to ‘Most Comprehensive Review’ of Evidence — But Patient Experiences Suggest More Applications

December 28, 2021June 2, 2024 Learn, Treatment

Psychedelic Spotlight speaks to a Field Trip Health patient and a psychotherapist, whose experiences suggest ketamine can also treat anxiety among other mental health issues.

Can Psychedelics Treat Alzheimer’s Disease?

December 27, 2021June 2, 2024 Learn, Research, Treatment

Since substances such as LSD and psilocybin have powerful anti-inflammatory properties, researchers argue that the microbiological action of psychedelics may therefore help fight brain-based symptoms in early Alzheimer’s patients.

Psychedelic Business Spotlight – December 24

December 24, 2021June 2, 2024 Business, Learn, Stock Reports

This week in psychedelic business news: FDA green lights a new psilocybin study; MindMed commences LSD treatment for ADHD; Sage Institute shuffles leadership.

MindMed Delays Project Lucy & Compass Pathways Has a Challenged Patent

December 24, 2021June 2, 2024 Listen, Psychedelic Spotlight Videos

MindMed’s Project Lucy is Delayed and Compass Pathways Has a…

FDA Green Lights Tryp Therapeutics’ Psilocybin Study on Binge Eating Disorder

December 23, 2021June 2, 2024 Learn, Research

The pharmaceutical company developing psilocybin-based compounds for diseases with unmet medical needs estimates a $2.9 billion market potential for such a treatment.